Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Supplement 1

Editorial Foreword - Milnacipran: recent findings in depression

Authors Montgomery S, Briley M

Published 24 August 2010 Volume 2010:6(Supplement 1) Pages 1—2

DOI https://doi.org/10.2147/NDT.S11773


Stuart Montgomery1, Mike Briley2 1Imperial College School of Medicine, London, England, UK; 2NeuroBiz Consulting and Communication, Castres, France

Milnacipran: recent findings in depression
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) which was first approved for the treatment of major depressive episodes in France in December 1996. It is currently marketed for this indication (as Ixel®, Toledomin®, Tivanyl® or Dalcipran®) in over 45 countries worldwide including Japan. It was approved for the management of fibromyalgia in the US in 2009.
This supplement, which is based on a symposium at the International Forum on Mood and Anxiety (IFMAD) held in Monaco in November 2009, highlights several recent clinical studies with milnacipran in depression.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]